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Objective: We investigated whether the inflammatory 
response and delayed onset of muscle soreness after a 
marathon are altered by resveratrol, a natural 
polyphenolic flavonoid antioxidant. 
Design: Double blind placebo-controlled randomised 
pilot study.  
Setting: London Marathon. 
Participants: Marathon race participants. 
Interventions: 7 healthy male athletes were randomised 
to receive Resveratrol (600 mg Resveratrol daily for 7 
days immediately before the marathon) or a placebo.  
Main Outcome Measurements: Blood samples taken 
48 hours before and 18-32 hours after the marathon 
were analysed for white blood cell count (WBC) and C-
reactive protein (CRP). A VAS score was taken at the 
same times as the blood samples to assess delayed onset 
muscle soreness. 
Results: There were no significant differences between 
the two groups in terms of changes occurring between 
pre- and post- tests for WBC, CRP or VAS.  
Conclusions: There were no differences in immune 
response or delayed onset muscle soreness between 
resveratrol and placebo after a marathon. Further 
investigations are needed with longer treatment time 
and higher doses, analysing additional parameters such 
interleukins for a possible effect of resveratrol on the 
inflammatory response due to extensive exercise. To 
avoid a type II error, 17 subjects in each group would be 
required. 








Running a marathon causes changes in immune 
response and microscopic damage to the muscles 1 . 
After prolonged running, substances released from 
injured muscle cells initiate an inflammatory response 
2,3,4.  Neutrophils, macrophages and lymphocytes 
exhibit the greatest changes in response to marathon 
competition 2,3. Changes in venous blood for up to 36 
hours after the marathon show neutrophilia, 
lymphopenia and an increase in pro-inflammatory 
cytokines (e.g. IL-6) 2,3,4,5. A study of 70 male and 
20 female runners showed an increase in the white 
blood cell count (+160%) and C reactive protein (CRP) 
(+2000%) immediately and 24 hours after a 42 km 
marathon race 6. Several other studies showed a 
marked increase of CRP 24 hours after a marathon 5,7 
. 
Resveratrol is a food supplement found in the seeds and 
skins of grapes, red wine, mulberries, peanuts and 
rhubarb. It may provide numerous health benefits, 
including prevention of a variety of illnesses, including 
cancer, cardiovascular disease and ischaemic injuries 
8,9,10. Resveratrol showed anti-inflammatory and 
immune-modulating actions via effective inhibition of 
cyclo-oxygenase (COX) activity 8,9,10,11,12,13,14 . 
The anti-inflammatory activities of resveratrol are 
related to impaired neutrophil function, absence of up-
regulation of tumour necrosis factor alpha (TNF-alpha) 
and reduced over expression of COX-2 12 . These 
anti-inflammatory properties have to our knowledge not 
been evaluated in sports medicine.  
The health benefits of resveratrol may derive from a 
group of substances called sirtuins, which activate or  
Resveratrol exerts no effect on inflammatory response and delayed onset muscle 
soreness after a marathon in male athletes. 




 MD, MBA, MSc, Perry M
3 
PhD , Benton S
4 





MD, MS, PhD 
1
 Centre for Sports and Exercise Medicine, Queen Mary University of London, Barts and The London School of Medicine 
and Dentistry, Mile End Hospital, 275 Bancroft Road, London E1 4DG, England 
2
 BUPA Center for Excellence Muskuloskeletal&Sports Medicine, London Basinghall Street, 4 Basinghall Street, 
London, EC2V 5BQ 
3 
 National Clinical Guideline Centre, Royal College of Physicians, London 
4 
 Barts Health NHS Trust, Department Clinical Biochemistry, Pathology and Pharmacy Building, Royal London 
Hospital, E1 2ES 
 
Markus Laupheimer  drlaupheimer@gmail.com 
Mark Perry <mcperry@live.co.uk>; 
Sally Benton <Sally.Benton@bartshealth.nhs.uk>; 
Peter Malliaras p.malliaras@qmul.ac.uk 
Nicola Maffulli n.maffulli@qmul.ac.uk 
Translational Medicine @ UniSa - ISSN 2239-9747 2014, 10(8): 38-42 
 
39 
Università degli Studi di Salerno 
suppress members of the forkhead box O (FOXO) 
group of transcription factors (figure 1).  
 
Figure 1: SIRT-1 activation pathways. Resveratrol and 
calorie restriction activate similar SIRT-1–mediated 
pathways whose actions result in prevention of common 
age-related diseases. (This figure has been taken from 




FOXOs activate or suppress specific genes leading to a 
decrease in apoptosis, an increase in anti-oxidative 
activities, DNA protection and anti-inflammatory 
effects 8,9,10,11,12,13.  Resveratrol modulates the 
expression of a number of genes involved in cell 
adhesion, muscle development, immune system 
regulation, neuroendocrine signalling, transcription and 
proteolysis 9,12,13 .  
Delayed onset muscle soreness (DOMS) is common and 
can occur independent of physical fitness levels. DOMS 
normally increases in intensity in the first 24 hours after 
exercise and peaks from 24 to 72 hours. Given the 
unknown aetiology of DOMS, many management 
modalities, including stretching, massage, cryotherapy 
or ibuprofen, have been proposed, but all have been 
found to be ineffective 15. Resveratrol has several 
possible influences on tissues, including being an anti-
oxidant and an anti-inflammatory, which could have an 
influence on DOMS (Figure 1).  
No human studies have yet investigated the effects of 
resveratrol on immune response and DOMs. This pilot 
study therefore evaluated the effect of resveratrol on 




Subjects and study design 
This was a randomised double-blind placebo-controlled 
trial involving the recruitment of 8 well-trained distance 
runners participating in the 2010 London Marathon. 
Runners were recruited from regional and national 
running clubs.  
Inclusion criteria were male gender and age 20 to 55 
years. The male gender and age were chosen to ensure a 
homogenous cohort and to optimise safety of the use of 
resveratrol as a food supplement before a marathon run. 
Exclusion criteria included a past medical history of 
chronic inflammatory medical conditions, muscle 
disorders or heart conditions, and a drug history of 
immune suppresants or anti-inflammatories.  
The study was undertaken with approval from the 
Ethics Committee of Queen Mary University of 
London. All subjects provided written informed consent 
before participation.  
Measurments and treatment allocation 
Pre-marathon measurements 
Before blood sampling a short questionnaire identified 
age, training volume and the exclusion criteria 
mentioned above. Intensity of training was evaluated by 
the average miles per week run three months before the 
London Marathon. Pre testing also included 
measurement of body weight and height to ensure that 
each participant had a similar dose per body weight of 
the Resveratrol.  
Athletes were also asked to attend a blood taking 
session two days before the London marathon. WBC 
and CRP were processed within 8 hours of blood 
letting. Blood samples were taken from the antecubital 
fossa and were collected directly into Sartedt Monovette 
(EDTA KE; Serum Gel), and processed within the 
Division of Blood Sciences at Barts and The London 
NHS Trust. Measurements for delayed onset muscle 
soreness were assessment of current pain, using a visual 
analogue scale (VAS) pain score. Each subject was 
asked to evaluate his level of perceived muscle 
soreness, with ratings as follows: 0 cm indicating 
complete absence of pain, and 10 cm indicating extreme 
soreness, with noticeable pain and stiffness at all times.  
After pre-testing, the eight participants were then 
randomly allocated to one of the two groups, as 
described below. 
Blinding and Randomisation: 
Before randomisation, two different sets of envelopes 
had been prepared by an independent person not 
associated with the study, containing 42 tablets for each 
participant. Four envelopes contained resveratrol tablets 
and Four envelopes contained placebo tablets. Each 
type of envelope was coded numerically (1 and 2), and 
the coding was not revealed to any of the study 
investigators until after data analysis. Another 
independent person then randomly allocated 
participants to blinded groups (labelled 1 or 2) using 
computer block randomisation, and participants 
received the appropriately labelled envelopes. 
Allocation concealment, as well as blinding of 
participants, assessor and data analyst were therefore 
assured during the entire study.  
Treatment 
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Four subjects received a one week course of resveratrol 
600 mg daily before the marathon, and four subjects 
received the same dose of placebo. Two 100 mg tablets 
were to be taken  three times each day, with the last two 
capsules to be taken on the day of the race. Participants 
were asked not to alter their diet in any way, and were 
not given any nutrition or hydration advice prior to the 
race.  
Post-marathon measurement: 
Blood was taken within18-32 hours after the marathon 
to compare the inflammatory response. Blood was taken 
from the anti-cubital fossa in an upright sitting position. 
Analysis of blood samples was undertaken as for the 
pre-test. Measurements for delayed onset muscle 
soreness were also undertaken as for the pre-test.  
Data Analysis 
Frequency histograms of data in each group were 
inspected for normality, and were deemed non-normally 
distributed. A comparison of the change in each 
variable (post minus pre marathon value) across the two 





One participant was excluded from the study as he 
developed a viral infection one week before the 
marathon, and was treated with anti-inflammatory 
medications. This athlete had been allocated during to 
the Resveratrol group and was not included in the 
analysis. All seven participants included in the analysis 
were male and finished the marathon between 3 hours 
10 minutes and 3 hours and 35 minutes. 
No medical problems or injuries were recorded. The 
characteristics of the participants are shown in table 1. 
There was no significant age, weight or height 
difference between the groups, but there was a trend for 
a height difference. All participants had an average 
weekly training mileage of more than 30 miles in the 3 








49 (41-55) 54 (40-55) 0.857 
Weight 
(kg) 
70 (66-72) 70 (68-78) 0.857 
Height 
(cm) 
171 (153-177) 183 (182-
185) 
0.057 
Table1. Characteristics of participants 
Safety Assessment 
None of the seven participants reported any adverse 
effects during the study period or during the marathon 
itself. 
Inflammation Assessment 
White Blood Cell Count 
There was no rise in the white blood cell count 
following the marathon in both groups combined. 
Comparing the increase of WBC between the 
resveratrol group and the placebo group there was no 
significant difference between the two groups. 
[p=0.857; median Resveratrol (IQR): 0.40 (-1.2 to 2.7); 
median Placebo (IQR): -0.2 (-0.7 to 1.05)] (Figure 2). 
 
Figure 2: Box plot of the increase in WBC in resveratrol 
and control groups 
 
C Reactive Protein 
There was a substantial increase in CRP in both groups 
combined, from before to after the marathon [median 
before (IQR): 5 (5 to 5); median after (IQR): 9 (5 to 10); 
p = 0.042]. Comparing the increase of CRP between the 
resveratrol group and placebo group showed no 
significant difference [median resveratrol increase 
(IQR): 2.0 (0.0 to 5.0); median placebo increase (IQR): 
4.5 (1.0 to 11.0); p=0.629] (Figure 3).   
 
Figure 3: Box plot of the increase in CRP in resveratrol 
and control groups 
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Delayed Onset of Muscle Soreness 
Assessment of current muscle pain before and 24 hours 
after the marathon showed increased pain 24h after the 
marathon in both groups combined [median before 1 (1 
to 2); median after 6.5 (3.75 to 8.5); p = 0.028]. There 
was no difference in the increase between the 
resveratrol group and the placebo group [median 
resveratrol increase (IQR): 4.0 (2.0 to 6.0); median 
placebo increase (IQR):  5.0 (3.0 to 9.0); p=0.70;] 
(figure 4). 
 
Figure 4: Box plot of the increase in VAS Score in 




This study did not detect significant differences 
between placebo and resveratrol in terms of their effects 
on increases in WBC, CRP or delayed DOMS after the 
London Marathon. 
There are several possible reasons for these results. 
First, a real difference could exist between resveratrol 
and placebo, but no difference was detected in our 
investigation. This could result from the low numbers of 
participants, and therefore a lack of statistical power. 
Post hoc power calculation showed that, to avoid a type 
II error, 17 runners in each group (34 in total) would be 
required for the CRP data.  Further work with larger 
sample sizes is therefore required to confirm or refute 
this.  
Secondly, the lack of detection of group differences 
could also be due to the timing of tests. Other studies 
have shown rises in WBC peaking 3 hours after the run, 
with a sustained increase over the next day up to 36 
hours 2,3,4,7,21. In the current study, blood was taken 
only once within 18-32 hours after the marathon, and so 
true effects may have missed.  
Thirdly, the dose of resveratrol in the current study may 
have been insufficient to show effects 23.  Mayers 
24 study fed mice a 0.1% resveratrol diet for 12 
weeks, and found no physiological effects of 
resveratrol, whereas Murase 25 found physiological 
differences in mice with a 0.2% resveratrol diet for 12 
weeks. Baur 
8
 found that long term treatment (over 1 
year), despite a 10-20 fold lower daily dose than other 
studies 14 , led to a remarkably improved insulin 
sensitivity and increased life span in mice fed a high fat 
diet. Therefore, it is possible that a one week course of 
resveratrol is not enough to influence the immune 
response after heavy exercise. In animal studies, a 
longer treatment time of 12 weeks prior the marathon 
appears to be a possible time frame for a follow up 
study. Future studies might also consider having two 
resveratrol groups with different daily doses.  
A final reason for the inconclusive results could be that 
resveratrol has no influence on WBC, CRP or DOMs 
response to marathon running in humans. Animal 
studies have shown that resveratrol influences 
interleukins and prostaglandins 5, 11, and further 
human studies might include such parameters as 
potentially more sensitive markers. 
A major strength of this study were the rigorous process 
of randomisation and blinding. Despite the small sample 
sizes, the groups were similar in terms of potential 
confounders such as training load and weight, and so 
threats to theinternal validity of the study were 
minimised.  
As already highlighted, a limitation of this study was 
the low number of participants, which probably 
increased the risk of a type II error. Although higher 
numbers were planned, with several efforts to recruit 
participants, marathon runners seem to be extremely 
resistant to alterations in their diet or using any form of 
food supplements. This should be taken into account 
when planning further studies and more time should be 
spent in providing information about resveratrol. 
CONCLUSIONS 
Despite basic scientific evidence for resveratrol as an 
anti-inflammatory food supplement, this pilot study 
could not detect a difference between resveratrol and 
placebo in terms of effects on post-marathon immune 
response or DOMS. Follow up studies should recruit at 
least 34 runners (17 in each group) to avoid a type II 
error, and consider a longer treatment time of 
resveratrol with a higher dose. The investigation of 
different serum indicators of inflammation, such as 
Interleukin-6, should also be considered. 
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